New Delhi:Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed retail prices of 9 formulations under the Drugs (Prices Control) Order, 2013. The authority has fixed the retail prices based on the decision of the 137th Authority meeting dated 15.9.2025. The list of formulations includes Aceclofenac, Paracetamol and Thiocolchicoside Tablets manufactured and marketed by Innova Captab/Macleods Pharmaceuticals; Dapagliflozin, Glimepiride and Metformin Hydrochloride (ER) Tablets manufactured and marketed by Akums Drugs and Pharmaceuticals/Blue Cross Laboratories; Sitagliptin, Glimepiride and Metformin Hydrochloride Tablets manufactured and marketed by Exemed Pharmaceuticals/Alembic Pharmaceuticals; and others. Also Read: NPPA Notifies Ceiling Prices for IV Fluids in Advanced Packaging Formats, Details This came in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; Manufacturer & Marketing Company Aceclofenac, Paracetamol & Thiocolchicoside Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Thiocolchicoside IP 8 mg M/s Innova Captab Ltd. / M/s Macleods Pharmaceuticals Ltd. Aceclofenac, Paracetamol & Thiocolchicoside Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Thiocolchicoside IP 4 mg M/s Innova Captab Ltd. / M/s Macleods Pharmaceuticals Ltd. Ibuprofen & Paracetamol Each 5 ml contains: Ibuprofen IP 100 mg Paracetamol IP 162.5 mg M/s Shiva Biogenetic Pharmaceuticals Pvt. Ltd. / M/s Mankind Prime Labs Pvt. Ltd. Dapagliflozin, Glimepiride & Hydrochloride (ER) Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP equivalent to Dapagliflozin 10 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg (as extended release) M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. Dapagliflozin, Glimepiride & Hydrochloride (ER) Tablets Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP equivalent to Dapagliflozin 10 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg (as extended release) M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. Sitagliptin, Glimepiride & Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg Pharmaceuticals / M/s Alembic Pharmaceuticals Ltd. Manufacturer & Marketing Company Hydrochloride Tablets Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg Sitagliptin, Glimepiride & Hydrochloride Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg Pharmaceuticals / M/s Alembic Pharmaceuticals Ltd. Sitagliptin, Empagliflozin & Hydrochloride (ER) Tablets Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg Pharmaceuticals / M/s Macleods Pharmaceuticals Ltd. Sitagliptin, Empagliflozin & Hydrochloride (ER) Tablets Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Empagliflozin 25 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg Pharmaceuticals / M/s Macleods Pharmaceuticals Ltd. The notification further added: (a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form V from the date of Notification as per paragraph 24 of the DPCO, 2013 to the NPPA through IPDMS and submit a copy to the State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above, i.e., who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/rules, including manufacturing license permission from the Competent Authority, i.e., the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the fixation of the retail price of such a formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with the specified strength for that Manufacturer & Marketing Companies as specified in the corresponding entries in columns (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.